SCHEDULE 13G: Investment Funds Disclose Significant Passive Stake in RELMADA THERAPEUTICS
Beneficial Ownership Disclosure
Squadron Master Fund LP and its affiliates have disclosed a passive ownership stake exceeding 5% in RELMADA THERAPEUTICS, INC., as detailed in a recent Schedule 13G filing.
Summary
- Squadron Master Fund LP, Squadron Capital Management LLC, and William Blank have filed a Schedule 13G, disclosing their beneficial ownership in RELMADA THERAPEUTICS, INC. Common Stock.
- Squadron Master Fund LP beneficially owns 1,821,835 shares, representing 5.5% of the class.
- Squadron Capital Management LLC and William Blank each beneficially own 2,050,000 shares, representing 6.2% of the class.
- The ownership percentages are based on 33,191,622 shares of common stock outstanding as of March 25, 2025.
- Squadron Capital Management LLC serves as an investment adviser to private funds, including Squadron Master Fund LP, and Mr. Blank is a Partner of Squadron Capital Management, LLC.
- All reporting persons share voting and dispositive power over their respective reported shares.
- The filing indicates a passive investment purpose, with the securities not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the issuer's performance or outlook. The passive nature of the investment suggests no immediate intent to influence company control.
Positives
- The disclosure of a significant passive stake by institutional investors like Squadron Master Fund LP and its affiliates can be interpreted as a vote of confidence in RELMADA THERAPEUTICS' long-term prospects, potentially attracting further investor interest.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment fund and its affiliates in a publicly traded company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holders and their passive investment intent, which can influence investor perception and confidence.
Key Dates
| Date | Description |
|---|---|
| 2025-03-25 | Date as of which 33,191,622 shares of common stock were outstanding, as represented by the Issuer in a Form 8-K. |
| 2025-04-24 | Date of event which requires the filing of this statement. |
| 2025-05-01 | Date the Schedule 13G was signed and filed. |
Keywords
RELMADA THERAPEUTICS, Squadron Master Fund LP, Squadron Capital Management LLC, William Blank, Schedule 13G, beneficial ownership, common stock, passive investment, institutional investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.